文献速递临床试验与 GCP

胸腔镜滑石粉喷洒与胸管滑石粉浆对恶性胸腔积液胸膜固定失败率的影响:一项随机临床试验

Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该多中心开放标签随机试验纳入330例恶性胸腔积液患者,比较局部麻醉下胸腔镜滑石粉喷洒(166例)与经胸管滑石粉浆(164例)的胸膜固定效果。90天时两组胸膜固定失败率分别为22%与24%,差异无统计学意义(调整OR 0.91,95%CI 0.54-1.55;24项预设次要结局均无显著差异。

要点

  • 90天胸膜固定失败率滑石粉喷洒组22% vs 浆液组24%,无显著差异。
  • 24项预设次要结局均无统计学显著差异。

核心结论

  • 在恶性胸腔积液患者中,胸腔镜滑石粉喷洒与经胸管滑石粉浆相比,90天胸膜固定失败率无显著差异。
  • 研究可能把握度不足,无法检出小而可能重要的差异。

研究设计与样本

  • 开放标签随机临床试验,在英国17家医院开展。
  • 2012年8月至2018年4月纳入330例患者,随访至2018年10月。
  • 纳入标准:年龄>18岁、确诊恶性胸腔积液、可接受局部麻醉胸腔镜。
  • 排除标准:需诊断性胸腔镜或存在肺不能复张证据。
  • 滑石粉喷洒组166例接受4g滑石粉喷洒,对照组164例经胸管给予4g无菌滑石粉浆。

主要发现

  • 共330例随机(平均年龄68岁;女性181例[55%]),320例(97%)纳入主要结局分析。
  • 90天胸膜固定失败率:滑石粉喷洒组36/161(22%),滑石粉浆组38/159(24%)。
  • 24项预设次要结局均无统计学显著差异。

临床怎么用

  • 对于可行局部麻醉胸腔镜的恶性胸腔积液患者,两种滑石粉给药方式在胸膜固定失败率上无显著差异。
  • 临床选择可综合考虑患者耐受性、资源可及性及操作偏好。

局限性

  • 研究可能把握度不足,无法检出小而可能重要的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Malignant pleural effusion (MPE) is challenging to manage. Talc pleurodesis is a common and effective treatment. There are no reliable data, however, regarding the optimal method for talc delivery, leading to differences in practice and recommendations. OBJECTIVE: To test the hypothesis that administration of talc poudrage during thoracoscopy with local anesthesia is more effective than talc slurry delivered via chest tube in successfully inducing pleurodesis. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized clinical trial conducted at 17 UK hospitals. A total of 330 participants were enrolled from August 2012 to April 2018 and followed up until October 2018. Patients were eligible if they were older than 18 years, had a confirmed diagnosis of MPE, and could undergo thoracoscopy with local anesthesia. Patients were excluded if they required a thoracoscopy for diagnostic purposes or had evidence of nonexpandable lung. INTERVENTIONS: Patients randomized to the talc poudrage group (n = 166) received 4 g of talc poudrage during thoracoscopy while under moderate sedation, while patients randomized to the control group (n = 164) underwent bedside chest tube insertion with local anesthesia followed by administration of 4 g of sterile talc slurry. MAIN OUTCOMES AND MEASURES: The primary outcome was pleurodesis failure up to 90 days after randomization. Secondary outcomes included pleurodesis failure at 30 and 180 days; time to pleurodesis failure; number of nights spent in the hospital over 90 days; patient-reported thoracic pain and dyspnea at 7, 30, 90, and 180 days; health-related quality of life at 30, 90, and 180 days; all-cause mortality; and percentage of opacification on chest radiograph at drain removal and at 30, 90, and 180 days. RESULTS: Among 330 patients who were randomized (mean age, 68 years; 181 [55%] women), 320 (97%) were included in the primary outcome analysis. At 90 days, the pleurodesis failure rate was 36 of 161 patients (22%) in the talc poudrage group and 38 of 159 (24%) in the talc slurry group (adjusted odds ratio, 0.91 [95% CI, 0.54-1.55]; P = .74; difference, -1.8% [95% CI, -10.7% to 7.2%]). No statistically significant differences were noted in any of the 24 prespecified secondary outcomes. CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, thoracoscopic talc poudrage, compared with talc slurry delivered via chest tube, resulted in no significant difference in the rate of pleurodesis failure at 90 days. However, the study may have been underpowered to detect small but potentially important differences. TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN47845793.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, et al. Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial. JAMA. 2020. PMID: 31804680. doi:10.1001/jama.2019.19997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。